{"paper_id":"c2460b2a-4de1-43c5-b0eb-7ab37a1e4da7","body_text":"Abstract\nSelective progesterone receptor modulators (SPRMs) have been extensively studied for potential efficacy in prevention and treatment of breast and other hormone dependent conditions. It has been suggested that SPRMs may increase the efficacy of tamoxifen and aromatase inhibitors in breast cancers with acquired resistance to these agents. SPRMs have also shown inhibitory effect on human uterine fibroids and endometriosis. Most in vitro and in vivo studies have shown that SPRMs preferentially suppress cell proliferation but may also induce apoptosis. In this review we summarize the effects of SPRMs on apoptosis in mammary and breast tumor cells as well as on uterine fibroids and uterine cells.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nAttardi B, Burgenson J, Hild S, Reel JR, Blye RP (2002) CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent anti-progestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188:111–123\nAttardi B, Burgenson J, Hild SA, Reel JR (2004) In vitro antiprogestational- antiglucocorticoid activity and progestin and glucocorticoid receptor binding activity of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 88:277–288\nBakker GH, Setyono-Han B, Henkelman MS et al (1987) Comparison of the actions of the anti-progestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 71:1021–1027\nBakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM (1989) Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing animal tumors. Endocrinology 125:1593–1598\nBakker GH, Setyono-Han B, Portengen H et al (1990) Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789–794\nBardon S, Vignon F, Montcourrier P, Rochefort H (1987) Steroid receptor-mediated cytotoxicity of an antiestrogen and an anti-progestin in breast cancer cells. Cancer Res 47:1441–1448\nBenakanakere I, Besch-Wolliford C, Carroll CE, Hyder SM (2010) Synthetic progestins differentially promote or prevent 7, 12-dimethylbenz(a)anthracene-induced mammary tumors in the Sprague-Dawley rat. Cancer Prev Res 3:1157–1167\nCepa M, Correia-da-Silva G, da Silva E, Roleira F et al (2008) New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. BMC Cell Biol 9:41–49\nChabbert-Buffet N, Meduri G, Bouchard P, Spitz IM (2005) Selective progesterone receptor modulators and progesterone antagonists: mechanism of action and clinical applications. Hum Reprod 11:293–307\nChappell PE, Lydon JP, Conneely OM, O’Malley BW, Levine JE (1997) Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 38:4147–4152\nChatterton RT Jr, Lydon JP, Mehta RG, Mateo ET, Pletz A, Jordan VC (2002) Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 188:47–52\nChen W, Ohara N, Wang J, Xu Q, Liu J et al (2006) A novel SPRM, asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 91:1296–1304\nChlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253\nChristov K (2009) To kill tumor cells or permanently paralyze them in senescence? J BUON 14:189–196\nChristov K, Grubbs C, Shilkaitis A, Juliana MM, Lubet R (2007) Short term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 13:5488–5496\nChui X, Schiff R, Arpino G et al (2005) Biology of progesterone receptor loss in breast cancer and its implication for endocrine therapy. J Clin Oncol 23:7221–7235\nDeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K (2003) Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 68:1019–1032\nDixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ (2002) Cell proliferation and apoptosis in human uterine leiomyomas and myometrial. Virchows Arch 44:53–62\nDressing GE, Lange CA (2009) Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids 10:6613–6617\nEngman M, Skoog L, Soderquist G, Dannielson KG (2008) The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 23:2072–2079\nForby B, Wiley TS (1998) Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 28:360–369\nFrank DW, Kitron KT, Murchism TE et al (1979) Mammary tumors and serum hormones in the bitch treated with medroxy-progesterone acetate or progesterone for four years. Fertil Steril 31:340–346\nFreeburg EM, Goyeneche AA, Telleria CM (2009) Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 34:743–755\nFulda S (2010) Cell death and survival signaling in oncogenesis. Klin Padiatr 222:340–344\nFulda S, Kroemer G (2011) Mitochondria as therapeutic targets for the treatment of malignant disease. Antioxid Redox Signal 15:2937–2949\nGaddy VT, Barett JT, Delk JN et al (2004) Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor expressing antiestrogen resistant breast cancer cells. Clin Cancer Res 10:5215–5225\nGalluzzi L, Kepp O, Kroemer G (2011) Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy. Oncogene 101:1038–1049\nGao Z, Matsuo H, Wang Y, Nakago S, Maruo T (2001) Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 86:5593–5599\nGrow DR, Coddington CC, Hsiu JG, Mikich Y, Hodgen GD (1996) Role of hypoestrogenism or sex steroid antagonism in adhesion formation after myometrial surgery in primates. Fertil Steril 66:140–147\nGrow DR, Reece MT, Hsiu JG, Adams L, Newcomb PM, Williams RF, Hodgen GD (1998) Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Fertil Steril 69:936–943\nHodgen GD, van Uem JF, Chillik CF, Danforth DR, Wolf JP, Neulen J, Williams RF, Chwalisz K (1994) Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 9(Suppl 1):77–81\nHoekstra AV, Sefton EC, Berry E, Lu Z, Hardt J, Marsh E, Yin P, Clardy J, Chakravarti D, Bulun S, Kim JJ (2009) Progestins activate the AKT pathway in Leiomyoma cells and promote survival. J Clin Endocrinol Metab 94:1768–1774\nHofseth LJ, Raafat AM, Osuch JR et al (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84:4559–4565\nIoffe OB, Zaino RJ, Mutter GL (2009) Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 22:450–459\nKester HA, van der Leede BM, van der Saag PT, van der Burg B (1997) Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 272:16637–16643\nKettel LM, Murphy AA, Mortola AJ, Liu JH, Ulmann A, Yen SSC (1991) Endocrine responses to long-term administration of the anti-progesterone RU486 in patients with pelvic endometriosis. Fertil Steril 56:402–407\nKlijn JGM, Setyono-Han B, Foekens JA (2000) Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65:825–830\nLange CA, Sartoris CA, Adbel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM (2008) Progesterone receptor action: translating studies in breast cancer models to clinical insights. In: Bernstein LM, Santen RJ (eds) Innovative endocrinology of cancer. Springer Science, New York, pp 94–111\nLeo JC, Lin VC (2008) The activities of progesterone receptor isoform A and b are differentially modulated by their ligands in a gene-selective manner. Int J Cancer 122:230–243\nLin V, Aw SE, Ng EH, Ng EHL, Tan MGK (2001) Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. Br J Cancer 85:1978–1986\nLin V, Jin R, Tan P, Aw AE, Woon CT, Bay BH (2003) Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am J Pathol 162:1781–1787\nLønning PE (2011) The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol 22:503–514\nLuo X, Yin P, Coon JS, Cheng YH, Wiehle RD, Bulun SE (2010) The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 93:2668–2673\nLydon JP, Ge G, Kittrell FS, Medina D, O’Malley BW (1999) Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 59:4276–4284\nMaruo T, Ohara N, Matsuo H, Xu Q, Chen W et al (2007) Effect of levonorgestrel-releasing IUS and progesterone receptor modulator CDB-2914 on uterine leiomyomas. Contraception 75:599–603\nMichna H, Schneider MR, Nishino Y, Etreby MF (1989a) Antitumor activity of the anti-progestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 14:275–288\nMichna H, Schneider MR, Nishino Y, Etreby MF (1989b) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34:447–453\nMichna H, Gehring S, Kuchnel W et al (1992) The antitumor potency of progesterone antagonists is due to their differentiation potential. J Steroid Biochem Mol Biol 43:203–210\nMurphy AA, Morales AJ, Kettel LM, Yen SS (1995) Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 63:187–190\nMutter GL, Bergeron C, Deligdisch L, Ferenczy A et al (2008) The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 21:591–598\nNagasawa H, Aoki M, Sakagami N, Ishida M (1988) Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Treat 12:59–66\nNeven P, van Gorp T, Deraedt K (2008) A gene signature of loss of estrogen receptor (ER) function and oxidative stress links ER-positive breast tumors with an absent progesterone receptor and a poor prognosis. Breast Cancer Res 10:109–113\nOltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681\nPoole AJ, Li Y, Kim Y et al (2006) Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467–1470\nRoeder H, Jayes F, Feng L, Leppert PC (2011) CDB-4124 does not cause apoptosis in cultured fibroid cells. Reprod Sci 18:850–857\nRohan TE, Negassa A, Chlebowski RT et al (2008) Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev 17:2337–2343\nRossow JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333\nSasaki H, Ohara N, Xu Q, Wang J, DeManno DA, Chwalisz K, Yoshida S, Maruo T (2007) A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 92:616–623\nSlayden OD, Brenner RM (2004) Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists. Arch Histol Cytol 67:393–409\nSpitz IM (2009) Clinical utility of progesterone receptor modulators and their effect in the endometrium. Curr Opin Obstet Gynecol 21:318–324\nSpitz IM, Wiehle RD, van As A (2009) Progesterone receptor modulators in the endometriosis: a new therapeutic option. In: Garcia-Velasco J, Rizk B (eds) Endometriosis: current management and future trends. Jaypee, New Delhi, pp 225–234\nSutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL (1988) Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48:5084–5091\nThe Million Women Study Collaborators (2003) Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362:419–427\nThe Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The women’s health initiative randomized controlled trial. JAMA 291:1701–1712\nTolcher AW (2005) Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol 3:635–642, http://www.ncbi.nlm.nih.gov/pubmed/16167050\nVargon V, Helguero LA, Bolado L, Rojas P et al (2009) Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinogenesis. Breast Cancer Res Treat 116:449460\nVitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12:385–389\nWiehle RD, Christov K, Mehta R (2007) Antiprogestin suppresses growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestins. Oncol Rep 18:167–174\nWiehle RD, Goldberg J, Brodniewicz T et al (2008) Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstetr Gynaecol 3:17–20\nWiehle R, Lantvit D, Yamada T, Christov K (2011) CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prev Res 4:414–424\nWu X, Lippman SM (2011) An intermittent approach for cancer chemoprevention. Nat Rev Cancer 11:879–885\nXu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T (2005) Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 90:953–961\nYin P, Lin Z, Chen YH, Marsh EE, Utsunomiya H et al (2007) Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab 92:4459–4466\nYoshida S, Ohara N, Xu Q, Chen W, Wang J et al (2010) Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 28:260–273\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2012 Springer Science+Business Media Dordrecht\nAbout this chapter\nCite this chapter\nChristov, K., Wiehle, R.D. (2012). Progesterone Receptor Modulators Induce Apoptosis in Mammary Tumors and Uterine Leiomyomas. In: Chen, G., Lai, P. (eds) Novel Apoptotic Regulators in Carcinogenesis. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4917-7_8\nDownload citation\nDOI: https://doi.org/10.1007/978-94-007-4917-7_8\nPublished:\nPublisher Name: Springer, Dordrecht\nPrint ISBN: 978-94-007-4916-0\nOnline ISBN: 978-94-007-4917-7\neBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)\nKeywords\nThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.","source_license":"CC0","license_restricted":false}